Physician profile
Daniel J Hahn
NPI 1598820508
$741.11
in general payments reported to CMS, 2019-2025
14 companies · $26.27 in 2025
The $26.27 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.88 · 2023: $511 · 2024: $188 · 2025: $26.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.01 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $140.88 | 2021-2023 | Wegovy |
| Revance Therapeutics, INC. | $115.74 | 2024 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $58.60 | 2023 | |
| Corcept Therapeutics | $47.59 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $34.03 | 2023-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $27.41 | 2023 | |
| Abbvie INC. | $26.44 | 2023 | |
| Medicomp INC | $25.47 | 2023 | Telepatch Cardiac Monitor |
| Mylan Specialty L.P. | $23.20 | 2023 | Yupelri |
| Amgen INC. | $22.87 | 2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2024 | Jardiance |
| Pfizer INC. | $14.18 | 2023 | |
| Lilly USA, LLC | $14.11 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.